MARKET

AMPE

AMPE

AMPIO PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.4320
+0.0590
+15.82%
After Hours: 0.4212 -0.0108 -2.50% 19:31 03/27 EDT
OPEN
0.3769
PREV CLOSE
0.3730
HIGH
0.4500
LOW
0.3563
VOLUME
3.07M
TURNOVER
--
52 WEEK HIGH
1.310
52 WEEK LOW
0.2600
MARKET CAP
68.59M
P/E (TTM)
-4.0678
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of AMPE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average AMPE stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.

EPS

AMPE News

More
  • Ampio Suspends Patient Enrollment in its Phase 3 Study of Ampion for Severe Osteoarthritis of the Knee and Explores Other Options to Complete Trial
  • PR Newswire · 4d ago
  • Ampio down 5% premarket after discontinuing patient enrollment in late-stage AP-013 trial amid COVID-19
  • Seeking Alpha - Article · 4d ago
  • Ampio is Preparing an Expanded Access FDA protocol to Study Nebulized Ampion as a Treatment for Moderate to Severe Acute Respiratory Distress Syndrome Associated with COVID-19
  • PR Newswire · 4d ago
  • Ampio to study nebulized Ampion as a treatment for COVID-19
  • Seeking Alpha - Article · 4d ago

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About AMPE

Ampio Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused primarily on the development of therapies to treat prevalent inflammatory conditions for which there are limited treatment options. The Company's two lead product candidates in development are Ampion for osteoarthritis of the knee and Optina for diabetic macular edema. Ampion is a sub 5000 molecular weight fraction of commercial human serum albumin (HSA). Optina is a low-dose formulation of danazol. The Ampio segment consists of its biopharmaceuticals compounds and the clinical trials associated with them. The Company is primarily developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process, and decreasing vascular permeability.
More

Webull offers kinds of Ampio Pharmaceuticals Inc stock information, including AMEX:AMPE real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AMPE stock news, and many more online research tools to help you make informed decisions.